Andera Partners Leads $67 Million Series A for Spiro Medical's Asthma Innovation

Andera Partners has led a $67 million Series A funding round for Spiro Medical, aiming to develop a novel neuromodulation system to treat asthma. The company, based in Irvine, CA, focuses on a first-of-its-kind Pulmonary Neuromodulation System, targeting both clinical and regulatory milestones in the U.S.

The investment group includes Omega Funds, Sherpa Healthcare Partners, HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd. The funding will drive the refinement of the PNM system and its path to U.S. regulatory approval.

Raymond W. Cohen, board chairman, emphasized the system's potential impact on asthma treatment. The executive team, with backgrounds from Vessix and Axonics, brings significant experience in neuromodulation systems, amplifying confidence in the project's success.